CH647757A5 - Derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee. - Google Patents
Derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee. Download PDFInfo
- Publication number
- CH647757A5 CH647757A5 CH3998/80A CH399880A CH647757A5 CH 647757 A5 CH647757 A5 CH 647757A5 CH 3998/80 A CH3998/80 A CH 3998/80A CH 399880 A CH399880 A CH 399880A CH 647757 A5 CH647757 A5 CH 647757A5
- Authority
- CH
- Switzerland
- Prior art keywords
- aps
- acid
- derivatives
- acetylhomo
- taurinate
- Prior art date
Links
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical class NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 title claims description 25
- 239000012528 membrane Substances 0.000 title claims description 4
- 230000000694 effects Effects 0.000 title description 5
- 239000011777 magnesium Substances 0.000 claims description 20
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 16
- 229910052749 magnesium Inorganic materials 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 7
- 229910052744 lithium Inorganic materials 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 10
- 229960003080 taurine Drugs 0.000 claims 5
- 230000004071 biological effect Effects 0.000 claims 2
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical class CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000936 membranestabilizing effect Effects 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003141 primary amines Chemical class 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 230000008485 antagonism Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- CXJAAWRLVGAKDV-UHFFFAOYSA-N acetyltaurine Chemical class CC(=O)NCCS(O)(=O)=O CXJAAWRLVGAKDV-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 229960004047 acamprosate Drugs 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000035873 hypermotility Effects 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WDIYOOMJRKTFKB-UHFFFAOYSA-M potassium;3-acetamidopropane-1-sulfonate Chemical compound [K+].CC(=O)NCCCS([O-])(=O)=O WDIYOOMJRKTFKB-UHFFFAOYSA-M 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- XJLMLOAYGUOMDM-UHFFFAOYSA-M sodium;3-acetamidopropane-1-sulfonate Chemical compound [Na+].CC(=O)NCCCS([O-])(=O)=O XJLMLOAYGUOMDM-UHFFFAOYSA-M 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
- C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7913207A FR2457281A1 (fr) | 1979-05-23 | 1979-05-23 | Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH647757A5 true CH647757A5 (fr) | 1985-02-15 |
Family
ID=9225819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH3998/80A CH647757A5 (fr) | 1979-05-23 | 1980-05-22 | Derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4355043A (en, 2012) |
| JP (2) | JPS5625146A (en, 2012) |
| AT (1) | AT372371B (en, 2012) |
| AU (1) | AU535785B2 (en, 2012) |
| BE (1) | BE883468A (en, 2012) |
| CA (1) | CA1152100A (en, 2012) |
| CH (1) | CH647757A5 (en, 2012) |
| DE (2) | DE19675017I2 (en, 2012) |
| ES (1) | ES491787A0 (en, 2012) |
| FR (1) | FR2457281A1 (en, 2012) |
| GB (1) | GB2051789B (en, 2012) |
| GR (1) | GR68547B (en, 2012) |
| IT (1) | IT1130455B (en, 2012) |
| MA (1) | MA18855A1 (en, 2012) |
| MX (1) | MX9203363A (en, 2012) |
| NL (2) | NL191789C (en, 2012) |
| OA (1) | OA06606A (en, 2012) |
| ZA (1) | ZA803051B (en, 2012) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU193197B (en) * | 1984-02-03 | 1987-08-28 | Egyt Gyogyszervegyeszeti Gyar | Preparatives regulating the growth of plants containing as reagent derivatives of n-substituated amin-prophansulphonic acid and process for production of the reagent |
| JPH0725771B2 (ja) * | 1992-06-18 | 1995-03-22 | 財団法人生産開発科学研究所 | ２−アミノエタンスルホン酸亜鉛錯化合物 |
| US20040208875A1 (en) * | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
| AU703540B2 (en) * | 1996-03-26 | 1999-03-25 | Meddiss, Incorporated | Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general |
| US6057373A (en) * | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| CA2318095C (en) * | 1998-01-13 | 2012-11-20 | Barry S. Fogel | Methods of treating tardive dyskinesia and other movement disorders |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US5952389A (en) * | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
| CA2319272C (en) * | 1998-01-27 | 2005-11-08 | Lipha | Novel aminoalkanesulphonic, -phosphonic and -phosphinic acid derivatives, their preparation and their use as medicaments |
| US20020022657A1 (en) * | 1998-02-11 | 2002-02-21 | Francine Gervais | Methods for modulating neuronal cell death |
| FR2775188B1 (fr) | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| DE60042896D1 (de) * | 1999-04-28 | 2009-10-15 | Bellus Health Int Ltd | Zusammensetzungen und verfahren zur behandlung von amyloidosis mit sulphonatderivaten |
| US6562836B1 (en) | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
| US7414076B2 (en) * | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| BRPI0517790A (pt) * | 2004-11-12 | 2008-10-21 | Neurochem Int Ltd | métodos e composições fluoradas para tratar doenças relacionadas à amilóide |
| EP1817305A2 (en) * | 2004-11-16 | 2007-08-15 | Neurochem (International) Limited | Compounds for the treatment of cns and amyloid associated diseases |
| CN101128421A (zh) * | 2004-12-22 | 2008-02-20 | 神经化学（国际）有限公司 | 治疗淀粉样相关疾病用的方法与组合物 |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| ES2352801T3 (es) * | 2005-12-22 | 2011-02-23 | Kiacta Sàrl | Tratamiento de nefropatía diabética. |
| KR101443573B1 (ko) | 2006-10-12 | 2014-11-03 | 비에이치아이 리미티드 파트너쉽 | 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클 |
| WO2008078176A1 (en) * | 2006-12-22 | 2008-07-03 | Bellus Health (International) Limited | Methods, compounds, and compositions for treating metabolic disorders and diabetes |
| KR100877134B1 (ko) * | 2007-05-03 | 2009-01-09 | 주식회사 엔지켐 | 아캄프로세이트 칼슘의 제조방법 |
| WO2009033061A1 (en) * | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US20090082464A1 (en) * | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| TW200932734A (en) * | 2007-10-15 | 2009-08-01 | Xenoport Inc | Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| CN101492400B (zh) * | 2008-01-22 | 2014-03-12 | 北京华禧联合科技发展有限公司 | 一种高纯度阿坎酸钙的制备方法 |
| DE102008048791A1 (de) * | 2008-09-24 | 2010-03-25 | Merck Patent Gmbh | Neue Kristallform von Calcium-3-Acetylaminopropan-1-sulfonat |
| IT1392327B1 (it) * | 2008-09-26 | 2012-02-28 | Laboratorio Chimico Int Spa | Nuova forma polimorfa del calcio acamprosato |
| CN104478766A (zh) * | 2014-12-25 | 2015-04-01 | 北京华禧联合科技发展有限公司 | 一种制备高纯度乙酰基高牛磺酸的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3039916A (en) * | 1961-03-27 | 1962-06-19 | West Laboratories Inc | Anionic iodine complexes |
| US3544597A (en) * | 1969-06-12 | 1970-12-01 | Rohm & Haas | Process for manufacturing sulfonated amides |
| JPS5418714B2 (en, 2012) * | 1974-10-08 | 1979-07-10 | ||
| FR2321285A1 (fr) * | 1975-08-18 | 1977-03-18 | Stanley Drug Products Inc | Agents antifibrinolytiques |
| FR2384751A1 (fr) * | 1977-03-23 | 1978-10-20 | Francaise Coop Pharma | Nouveaux derives de la taurine a activite neuro-musculaire renforcee |
| US4233229A (en) * | 1978-01-03 | 1980-11-11 | Gaf Corporation | Preparation of salt-free N-acyl taurines |
-
1979
- 1979-05-23 FR FR7913207A patent/FR2457281A1/fr active Granted
-
1980
- 1980-05-19 US US06/150,946 patent/US4355043A/en not_active Expired - Lifetime
- 1980-05-20 GR GR62000A patent/GR68547B/el unknown
- 1980-05-21 DE DE1996175017 patent/DE19675017I2/de active Active
- 1980-05-21 DE DE19803019350 patent/DE3019350A1/de active Granted
- 1980-05-22 ZA ZA00803051A patent/ZA803051B/xx unknown
- 1980-05-22 IT IT67807/80A patent/IT1130455B/it active
- 1980-05-22 GB GB8016956A patent/GB2051789B/en not_active Expired
- 1980-05-22 CH CH3998/80A patent/CH647757A5/fr not_active IP Right Cessation
- 1980-05-22 MA MA19051A patent/MA18855A1/fr unknown
- 1980-05-22 AT AT0274580A patent/AT372371B/de not_active IP Right Cessation
- 1980-05-23 NL NL8002997A patent/NL191789C/xx not_active IP Right Cessation
- 1980-05-23 JP JP6796380A patent/JPS5625146A/ja active Granted
- 1980-05-23 CA CA000352613A patent/CA1152100A/en not_active Expired
- 1980-05-23 ES ES491787A patent/ES491787A0/es active Granted
- 1980-05-23 AU AU58697/80A patent/AU535785B2/en not_active Expired
- 1980-05-23 BE BE0/200755A patent/BE883468A/fr not_active IP Right Cessation
- 1980-05-23 OA OA57119A patent/OA06606A/xx unknown
-
1990
- 1990-10-17 JP JP2276598A patent/JPH03148219A/ja active Granted
-
1992
- 1992-06-25 MX MX9203363A patent/MX9203363A/es unknown
-
1997
- 1997-01-22 NL NL970003C patent/NL970003I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2051789A (en) | 1981-01-21 |
| AT372371B (de) | 1983-09-26 |
| AU5869780A (en) | 1980-11-27 |
| FR2457281B1 (en, 2012) | 1983-10-07 |
| DE3019350A1 (de) | 1980-12-04 |
| NL8002997A (nl) | 1980-11-25 |
| JPH0317825B2 (en, 2012) | 1991-03-11 |
| IT1130455B (it) | 1986-06-11 |
| DE3019350C2 (en, 2012) | 1989-11-30 |
| US4355043A (en) | 1982-10-19 |
| FR2457281A1 (fr) | 1980-12-19 |
| NL970003I2 (nl) | 1997-08-01 |
| GR68547B (en, 2012) | 1982-01-18 |
| CA1152100A (en) | 1983-08-16 |
| NL970003I1 (nl) | 1997-04-01 |
| JPH03148219A (ja) | 1991-06-25 |
| JPS5625146A (en) | 1981-03-10 |
| ES8101042A1 (es) | 1980-12-16 |
| NL191789C (nl) | 1996-08-02 |
| ZA803051B (en) | 1981-06-24 |
| MX9203363A (es) | 1992-07-01 |
| ATA274580A (de) | 1983-02-15 |
| AU535785B2 (en) | 1984-04-05 |
| JPH0524135B2 (en, 2012) | 1993-04-06 |
| GB2051789B (en) | 1983-04-27 |
| ES491787A0 (es) | 1980-12-16 |
| NL191789B (nl) | 1996-04-01 |
| BE883468A (fr) | 1980-11-24 |
| DE19675017I2 (de) | 2001-04-26 |
| IT8067807A0 (it) | 1980-05-22 |
| OA06606A (fr) | 1981-08-31 |
| MA18855A1 (fr) | 1980-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH647757A5 (fr) | Derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee. | |
| CA1203242A (fr) | Procede de preparation de sels derives de l'acide 3- hydroxybutanoique et d'une base organique aminee, et les sels ainsi obtenus | |
| CA2024419C (fr) | Nouveaux sels de metaux bivalents de l'acide n,n-di(carboxymethyl) amino-2cyano-3carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| EP0068999B1 (fr) | Dérivés d'aryl-1 aminométhyl-2 cyclopropanes carboxamides (Z), leur préparation et leur application en tant que médicaments utiles dans le traitement des troubles du système nerveux central | |
| RU2128160C1 (ru) | Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция | |
| JPH10508613A (ja) | 内部寄生虫を駆除するためのジオキソモルホリンの使用、新規ジオキソモルホリンおよびそれらの製造方法 | |
| EP0110781A1 (fr) | (Amino-2 éthyl)-6 benzoxazolinones substituées, leur préparation et une composition pharmaceutique les contenant | |
| CH641759A5 (fr) | Phenethanolamines et composition pharmaceutique antineoplastique les contenant. | |
| CA2101058A1 (fr) | Composes a structure guanidique et composition pharmaceutique les contenant | |
| EP0087378B1 (fr) | Ethers-oximes d'alcoylaminoalcools comme médicaments, produits nouveaux et procédés pour leur préparation | |
| Finkelstein | The preparation of β-aminoethanephosphonic acid | |
| EP0239436B1 (fr) | Nouveau dérivé tricyclique dénommé acide (chloro-3 méthyl-6 dioxo-5,5 dihydro-6, 11 dibenzo (c,f) thiazépine (1,2) yl-11 amino) -5 pentanoique, son procédé de préparation et les compositions pharmaceutiques qui le contiennent | |
| EP0024960A2 (fr) | Nouvelles phénoxyamines hétérocycliques substituées, procédé pour leur préparation et leur application comme anesthésiques locaux | |
| FR2633619A1 (fr) | Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant | |
| FR2492821A1 (fr) | Derives de la pyrimidine, leur procede de preparation et les compositions pharmaceutiques les contenant | |
| CH642378A5 (fr) | Nouveau derive du paracetamol, son procede de preparation et son utilisation en therapeutique. | |
| KR900006124B1 (ko) | Gem-디할로 및 테트라할로-1,12-디아미노-4,9-디아자-도데칸 및 이들의 제조방법 | |
| CH658786A5 (fr) | Medicaments qui contiennent d'alpha-(n-pyrrolyl)-acides ou de leurs sels ou esters. | |
| CH615673A5 (en, 2012) | ||
| CA1140111A (fr) | PROCEDE DE PREPARATION D'UN NOUVEAU DERIVE DU (20S) 3.alpha.- /(AMINO-ACETYL)AMINO/ 5.alpha.-PREGNAN-20-OL ET DE SES SELS | |
| FR2508444A1 (fr) | Nouveaux derives sulfonyle du tryptophane utiles en tant que medicaments et leur procede de preparation | |
| LU83775A1 (fr) | Derives de naphtyridine,leur preparation et leur application en therapeutique | |
| CH628321A5 (en) | Process for the preparation of derivatives of isobutyramide and medical composition containing these derivatives | |
| FR2463124A1 (fr) | Acides 2-amino-3-(alkylthiobenzoyl)-phenylacetiques et derives, et leur utilisation comme anti-inflammatoires, analgesiques, et inhibant l'agglomeration des plaquettes sanguines | |
| FR2648814A1 (fr) | L'alpha (tert-butyl-aminomethyl-3,4-dichlorobenzyl)thioacetamide, son procede de preparation et son application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUE | Assignment |
Owner name: LES LABORATOIRES MERAM TRANSFER- LIPHA LYONNAISE I |
|
| NV | New agent |
Representative=s name: BOVARD AG PATENTANWAELTE |
|
| SPCF | Supplementary protection certificate filed |
Free format text: OICM 53090/950829, 960227 |
|
| SPCC | Certificates - corrections |
Free format text: OICM 53090/19950829, 19960227 |
|
| SPCG | Supplementary protection certificate granted |
Free format text: OICM 53090/19950829, 19960227, EXPIRES:20050521 |
|
| PFA | Name/firm changed |
Owner name: LIPHA LYONNAISE INDUSTRIELLE PHARMACEUTIQUE -DANN |
|
| NV | New agent |
Representative=s name: HUG INTERLIZENZ AG |
|
| PL | Patent ceased | ||
| SPCP | Certificates - modification of firm |
Free format text: LIPHA S.A. 37, RUE ST. ROMAIN LYON (FR)TRANSFER-LIPHA 37, RUE ST. ROMAIN LYON (FR) |
|
| SPCP | Certificates - modification of firm |
Free format text: LIPHA LYONNAISE INDUSTRIELLE PHARMACEUTIQUE TRANSFER- LIPHA S.A. |